Verve Therapeutics, Inc. (NASDAQ:VERV) Insider Sells $11,524.55 in Stock

Verve Therapeutics, Inc. (NASDAQ:VERV) insider Joan Nickerson sold 2,777 shares of the company’s stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $4.15, for a total transaction of $11,524.55. Following the sale, the insider now directly owns 17,420 shares in the company, valued at approximately $72,293. This trade represents a 13.75 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Verve Therapeutics Stock Down 1.5 %

Shares of VERV stock traded down $0.06 on Thursday, reaching $3.85. The company’s stock had a trading volume of 2,477,105 shares, compared to its average volume of 1,431,392. The company has a market capitalization of $341.86 million, a P/E ratio of -1.57 and a beta of 1.77. Verve Therapeutics, Inc. has a 12-month low of $3.69 and a 12-month high of $9.31. The stock’s 50 day simple moving average is $6.78 and its 200-day simple moving average is $6.05.

Verve Therapeutics (NASDAQ:VERV) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.14. The firm had revenue of $13.08 million during the quarter, compared to the consensus estimate of $3.94 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. Research analysts expect that Verve Therapeutics, Inc. will post -2.49 EPS for the current year.

Wall Street Analysts Forecast Growth

VERV has been the topic of a number of recent research reports. Guggenheim restated a “buy” rating on shares of Verve Therapeutics in a research note on Tuesday, March 25th. Royal Bank of Canada cut their price target on Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating for the company in a report on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Verve Therapeutics in a report on Tuesday, March 25th. Finally, William Blair reaffirmed an “outperform” rating on shares of Verve Therapeutics in a report on Friday, February 21st. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $25.50.

Hedge Funds Weigh In On Verve Therapeutics

A number of institutional investors have recently made changes to their positions in VERV. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Verve Therapeutics by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 17,952 shares of the company’s stock worth $101,000 after acquiring an additional 1,676 shares during the last quarter. Rhumbline Advisers raised its position in Verve Therapeutics by 1.9% during the fourth quarter. Rhumbline Advisers now owns 111,203 shares of the company’s stock valued at $627,000 after purchasing an additional 2,093 shares in the last quarter. Arizona State Retirement System lifted its stake in Verve Therapeutics by 15.8% during the fourth quarter. Arizona State Retirement System now owns 19,593 shares of the company’s stock worth $111,000 after purchasing an additional 2,669 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Verve Therapeutics by 5.8% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 50,230 shares of the company’s stock worth $313,000 after purchasing an additional 2,742 shares during the last quarter. Finally, Invesco Ltd. boosted its holdings in shares of Verve Therapeutics by 5.7% in the 4th quarter. Invesco Ltd. now owns 57,140 shares of the company’s stock worth $322,000 after purchasing an additional 3,080 shares in the last quarter. Institutional investors own 97.11% of the company’s stock.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.